Incyte Corp.

NASDAQ:INCY  
79.28
+0.66 (+0.84%)
Products, Regulatory

Morphosys And Incyte Announce Positive CHMP Opinion For Tafasitamab In Combination With Lenalidomide

Published: 06/25/2021 11:52 GMT
Incyte Corp. (INCY) - Morphosys and Incyte Announce Positive Chmp Opinion for Tafasitamab in Combination With Lenalidomide for the Treatment of Adults With Relapsed Or Refractory Diffuse Large B-cell Lymphoma.
If Approved, Tafasitamab in Combination With Lenalidomide Would Represent an Important New Therapeutic Option for Eligible Dlbcl Patients in European Union.
Positive Opinion From Chmp is Based on Data From Phase 2 L-mind Study Evaluating Tafasitamab in Combination With Lenalidomide As a Treatment for Patients With Relapsed Or Refractory Dlbcl.